Navigation Links
Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
Date:9/16/2011

r showing long-term QNEXA data on glycemic effects in type 2 diabetic patients (N=145) from the two-year SEQUEL study. In the SEQUEL diabetic sub-group, greater percent weight loss was achieved with QNEXA when compared to placebo at week 108 (9.0% in the mid- and top-dose QNEXA and 2.0% placebo within the diabetic sub-group P≤0.0003). Within the diabetic sub-group, improvements were seen in fasting glucose, fasting insulin and hemoglobin A1c in the QNEXA-treated groups. The QNEXA-treated patients also had reduced utilization of concomitant antidiabetic medications as compared to placebo (P=0.0130).  

A poster presentation by Dr. Hermann Toplak from the Medical University of Graz, Austria focused on long-term QNEXA treatment, sustained weight loss, reversal of metabolic syndrome and improvements in associated traits. Of the 675 patients enrolled in SEQUEL, 451 (66.8%) met the criteria for metabolic syndrome. Average percent weight loss at week 108 within the metabolic syndrome sub-group was 11.1% mid-dose QNEXA, 12.2% top-dose QNEXA and 2.8% placebo (P<0.0001 vs. placebo). The percentage of patients demonstrating resolution of metabolic syndrome was significantly higher within the QNEXA treatment arms at week 108 [22.4% mid-dose (P=0.0031), 27.6% top-dose (P<0.0001)] vs. 9.2% with placebo. Conversely, the percentage of patients without metabolic syndrome at baseline, who progressed to metabolic syndrome at week 108, were higher in the placebo group at 60% vs. 23% with top-dose QNEXA (P= 0.0050).In all three analyses, the safety profile was consistent across subpopulations and the most common adverse events seen were upper respiratory infection, constipation, tingling, runny nose and dry mouth.

About QNEXA Controlled Release CapsulesQNEXA [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. VIVUS Provides Regulatory Update on QNEXA
2. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
3. Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity
4. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
5. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
6. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
7. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
8. VIVUS Provides Regulatory Update on QNEXA NDA
9. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
10. A Majority of Surveyed PCPs and Endocrinologists Indicate that they will Prescribe Contrave, Lorqess and Qnexa if these Therapies are Approved for Obesity
11. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... the "US Self-monitoring Blood Glucose Market" report ... This market insight focuses on the ... the United States . Reimbursement analysis and ... product analyses for more than 73 SMBG meters have ...
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held medical ... has been appointed Interim Chief Executive Officer of the ... succeeds Ken Berger .  "The Board of Directors ... leading ConvaTec over the past three years," said ... Directors.  "We are confident that the company is well ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... issued the following open letter to shareholders from ... Med. Sc. Dear RXi Shareholders, ... of inaccurate statements posted on certain social media ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... of Novel Proteasome Inhibitor in ... Patients with Relapsed Solid Tumors, SOUTH SAN ... South Texas Accelerated Research Therapeutics (START),today announced the enrollment of ... Proteolix,s investigational drug, carfilzomib (PR-171).,START is participating in the study ...
... Protects the Ocular Surface Following Exposure to ... Dry Eye Symptoms, LAGUNA HILLS, Calif., Oct. 9 ... ALTY-0501, demonstrated statistically,significant advantages over vehicle in its ability ... Phase 2 study. The Phase 2 study utilized ...
Cached Medicine Technology:Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors 2Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors 3Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 2Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 3
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... Thousands of transvaginal mesh lawsuits ( ... number of multidistrict litigations currently underway in U.S. District ... reports. According to an Order issued on December 2, ... Status Conference in all of the proceedings on January ... to submit a proposed agenda to the Court by ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 Each ... visits and 2 million hospital admissions across the nation ... Prevention ). The CDC’s National Hospital Ambulatory Medical ... through a survey conducted in 2010. They estimated that ... visits that resulted in a primary diagnosis of broken ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in the ... holiday season, AlignLife looks forward to their annual toy drive. ... Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as well ... able to give kids toys for Christmas who would be ... of our patients." , The 70 toys were donated to ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... Health plan members who individually purchase their plans ... satisfied with their health plan experience, compared with ... according to the J.D. Power and Associates 2009 ... today.(Logo: http://www.newscom.com/cgi-bin/prnh/20050527/LAF028LOGO-a )Now in its third ...
... with Allen Cardoza , Los Angeles, California, April ... 2 Our special guest this week is Dr. ... practice. Shelly has been a coach and presenter to ... as a Doctor of Psychology and a Licensed Marriage ...
... found in all living cells could serve as a ... or nicotinamide adenine dinucleotide, is a key coenzyme -- ... enzyme -- found mostly in the inner membrane of ... series of biochemical reactions that involve various enzymes to ...
... on how a small hospital improved charge capture ... day using Craneware,s Bill AnalyzerATLANTA, April 2 ... provider of financial performance solutions, announced today it ... Hospital at the annual conference of the Healthcare ...
... (formerly Diagnostic Ultrasound Corporation) an innovator in medical ... care providers, is celebrating its 25th anniversary this ... 2, 1984 founding in a modest basement workshop, ... with the company,s products now used by health ...
... is a statement from Jeff Levi, PhD, Executive Director of ... of the new report Beyond Health Care: Directions to ... Commission to Build a Healthier America:"Every American should have the ... be. And every community should be safe from threats ...
Cached Medicine News:Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 2Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 3Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 4Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 5Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 6Health News:Naturally fluorescent molecules may serve as cancer biomarker 2Health News:Naturally fluorescent molecules may serve as cancer biomarker 3Health News:Craneware and St. Joseph to Present Revenue Enhancement Success Story at HIMSS 2Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Celebrates 25 Years of Improving Patient Care 2Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Celebrates 25 Years of Improving Patient Care 3Health News:Trust for America's Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America 2Health News:Trust for America's Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America 3
Inquire...
... new QIAvac 24 Plus vacuum manifold allows processing of ... tedious loading and unloading of spin columns into and ... Plus offers: Time savings ... DNA, PCR products, and RNA Convenience ...
... Kuderna-Danish, Rotary, Vacuum-Style and Nitrogen Blow-Down Evaporators. For over ten years TurboVap concentration technology has received enormous ... ... ... ...
... The UltraVac manifold is designed ... The manifold holds one deep ... Samples and buffers are drawn through ... collection plates or microplates. The ...
Medicine Products: